Evidence map›Paper›PMID 36410831›Full record

ArticleBMJ open2022

Adoptive immunotherapy with natural killer cells from peripheral blood CD34

Masahiro Ohira, Tsuyoshi Kobayashi, Yuka Tanaka, Yuki Imaoka, Koki Sato, Koki Imaoka, Ryosuke Nakano, Marlen Doskali, Jinlian Piao, Mayuna Nakamura and 14 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 2 institutions in 1 country.

Masahiro OhiraDepartment of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.ORCID 0000-0002-5433-5303
Tsuyoshi KobayashiDepartment of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Yuka TanakaDepartment of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Yuki ImaokaDepartment of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Koki SatoDepartment of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Koki ImaokaDepartment of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Ryosuke NakanoDepartment of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Marlen DoskaliDepartment of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Jinlian PiaoDepartment of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Mayuna NakamuraDepartment of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Tetsumi YoshidaDepartment of Hematology and Oncology, Hiroshima University Hospital, Hiroshima, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Hiroshima University Hospital, Hiroshima, Japan.
Reo KawanoClinical Research Center, Hiroshima University Hospital, Hiroshima, Japan.
Kenichi YoshimuraMedical Center for Translational and Clinical Research, Hiroshima University, Hiroshima, Japan.
Keiko UedaClinical Research Center, Hiroshima University Hospital, Hiroshima, Japan.ORCID 0000-0002-4830-4607
Natsuko TamuraClinical Research Center, Hiroshima University Hospital, Hiroshima, Japan.
Taizo HirataClinical Research Center, Hiroshima University Hospital, Hiroshima, Japan.
Michio ImamuraDepartment of Gastroenterology, Hiroshima University, Hiroshima, Japan.
Hiroshi AikataDepartment of Gastroenterology, Hiroshima University, Hiroshima, Japan.
Naoki TanimineDepartment of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Shintaro KurodaDepartment of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Hiroyuki TaharaDepartment of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Kentaro IdeDepartment of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Hideki OhdanDepartment of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan hohdan@hiroshima-u.ac.jp.
Hiroshima University · JPHiroshima University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHepatocellular carcinoma (HCC) remains a major clinical problem as more than half of these cases recur after radical resection. Natural killer (NK) cells are at the forefront of the innate immune system and attack microcarcinomas and circulating tumour cells. The objective of this study was to evaluate the feasibility and toxicity of peripheral blood CD34 METHODS AND ANALYSIS: This is an open-label, single-arm, single-centre phase I study. Patients who have undergone initial hepatectomy for HCC with three or more risk factors for recurrence (≥10 ng/mL of Alpha fetoprotein (AFP), ≥360 mAU/mL of PIVKA-II, multiple tumours and ≥3 peripheral blood circulating tumour cells) will be enrolled and be treated with three peripheral blood CD34 ETHICS AND DISSEMINATION: Ethical approval of the trial was obtained from the Certified Committee for Regenerative Medicine Hiroshima University in Japan. The trial results will be shared with the scientific community at international conferences and by publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: jRCTb060200020.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsNeoplastic Cells, CirculatingCell Adhesion MoleculesClinical Trials, Phase I as TopicHepatectomyHumansImmunotherapy, AdoptiveKiller Cells, NaturalNeoplasm Recurrence, LocalStem CellsCell Adhesion MoleculesHepatobiliary surgeryIMMUNOLOGYSURGERY

Identifiers

PMID36410831
PMCPMC9680173
OpenAlexW4309531243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.